

2018 National Preferred Formulary

The National Preferred Formulary (NPF) is a powerful tool that enables our clients to achieve optimum trend management while preserving individual choice and access to clinically effective generic and brand-name drugs.

More Americans obtain their pharmacy benefit coverage through the NPF than any other formulary. Over the last five years, formulary exclusions have delivered **more than \$7.4 billion in year-over-year client savings** without compromising the member experience.


Even More Value in 2018

For the 2018 benefit year, Express Scripts will introduce 64 new drug exclusions to the NPF. Combined with prior year exclusions, a total of 159 out of 3,791 available drugs will be excluded.

Our formulary is designed to bring the greatest value to our clients and members while increasing the use of the lowest net-cost products. In 2018, we expect our formulary exclusions to deliver an additional \$2.5 billion in client savings.

A Proven Member Experience

The new exclusions on our 2018 NPF will only impact 0.67% of our members while continuing to add value. Of course, new exclusions mean that some members will be asked to use a different medication that achieves the same health outcome at a lower cost. However, if a patient has a rare clinical need that requires a medication that is not on the formulary, we have provided a clear pathway to have that drug covered.





Robust Communications

Beginning this fall, we will notify affected members in the following ways:

- **Personalized notifications and reminder communications** will be sent to affected members before January 1, 2018. These communications will include a list of alternative medications and information for facilitating conversion to a preferred product.
- **Targeted communications** and information at Express-Scripts.com will provide additional details about preferred options and generic alternatives.
- **Targeted alerts** will be sent to members who attempt to fill an excluded product throughout 2018.

We also have a comprehensive provider communication plan. Beginning this fall, top prescribers and network pharmacies will receive:

- **Announcement and reminder communications** that detail upcoming exclusions and preferred alternatives.
- **Point-of-sale and point-of-care alerts** detailing patient-specific exclusions and covered alternatives.

2018 National Preferred Formulary New Exclusions

Below is a summary of the exclusions going into effect on January 1, 2018.

Multi-Source Brand Exclusions

The generic equivalents of the following brand-name medications are covered under the NPF. These generic medications meet strict standards and have been approved by the FDA. These generic products contain the same active ingredients as their corresponding brand-name medications, although they may have a different color or shape.

ABILIFY	CYTOMEL	MINASTRIN 24 FE	SEROQUEL/XR	XANAX/XR
ACIPHEX	EFFEXOR XR	NASONEX	SINGULAIR	XENAZINE
ADDERALL	IMITREX	PLAQUENIL	STRATTERA	ZEGERID
ANDROGEL 1%	INDERAL LA	PLAVIX	TIKOSYN	ZETIA
ANUSOL-HC	INTUNIV	PREVACID	TOBI SOLUTION	ZOLOFT
ATACAND/HCT	LEXAPRO	PRISTIQ	TRIBENZOR	ZYFLO CR
AZOR	LIBRAX	PROTONIX	VALIUM	
BENICAR/HCT	LIDODERM	PROVIGIL	VALTREX	
BUPAP	LOVENOX	PROZAC	VYTORIN	
CYMBALTA	LUNESTA	PULMICORT RESPULES	WELLBUTRIN SR	

Single-Source Brand Exclusions

The following drug classes have new exclusions for 2018. Please note that product placement for Hepatitis C and treatment for Inflammatory Conditions are under consideration and changes may occur based upon changes in market dynamics and new product launches. The full list of excluded products will be available on or before September 15, 2017.

Drug Class	Excluded Medications	Preferred Alternatives
Long-Acting Opioid Oral Analgesics	OPANA ER, OXYCODONE ER	hydromorphone ER, morphine sulfate ER, oxymorphone ER, HYSINGLA ER, NUCYNTA ER, OXYCONTIN
Transmucosal Fentanyl Analgesics	ABSTRAL*, FENTORA*, LAZANDA	fentanyl citrate lozenges
Estrogen and Estrogen Modifiers for Vaginal Symptoms	FEMRING	estradiol patches, estradiol tablets, yuvafem, ESTRACE Cream, ESTRING, PREMARIN Cream, PREMARIN Tablets
Somatostatin Analogs	SANDOSTATIN LAR DEPOT, SIGNIFOR LAR	SOMATULINE DEPOT
Irritable Bowel Syndrome and Chronic Constipation Agents	TRULANCE	AMITIZA, LINZESS
Proton Pump Inhibitors	ACIPHEX SPRINKLE, PREVACID SOLUTAB, PRILOSEC Suspension, PROTONIX Suspension	esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, NEXIUM Packets
Granulocyte Colony Stimulating Factors	NEUPOGEN	GRANIX, ZARXIO
Osteoporosis Therapy	FORTEO	alendronate, ibandronate, risedronate, zoledronic acid, TYMLOS
Antiglaucoma Drugs (Beta-Adrenergic Blockers)	ISTALOL*, TIMOPTIC OCUDOSE	betaxolol drops, levobunolol drops, timolol drops, ALPHAGAN P 0.1%, COMBIGAN
Ophthalmic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	ACUVAIL*, NEVANAC	bromfenac drops, diclofenac drops, ketorolac drops, ILEVRO, PROLENSA
Renal Disease—Phosphate Binders	FOSRENOL, RENAGEL	sevelamer carbonate, PHOSLYRA, VELPHORO
Respiratory—Epinephrine Auto-Injector Systems	AUVI-Q*, EPINEPHRINE AUTO-INJECTOR (by A-S Medication, Impax & Lineage)	EPINEPHRINE AUTO-INJECTOR (by Mylan), EPIPEN, EPIPEN JR.

*Current 2017 exclusion in this class

For more information, please contact your Express Scripts representative.